A Phase 1/2 interventional study of PLX2853 20 mg and Olaparib in Metastatic Castration-resistant Prostate Cancer, sponsored by Opna Bio LLC. Terminated at 8 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Opna Bio LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 307 studies in Adenocarcinoma with a site in United States — 48 open to participants now, 75 under way, 7 of them phase 3. Adenocarcinoma · United States.
Among the 307 studies in Adenocarcinoma with a site in United States, this one is the 209th largest by enrollment of the 271 interventional ones that give a count, is one of 15 that started in 2020, is one of 42 in phase 1/2, and was the 228th registered.
620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.
Browse Adenocarcinoma studies →48 of the 307 studies in Adenocarcinoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
RayzeBio, Inc. · Sites in United States
Ages 18+ · Men only
Monte Rosa Therapeutics, Inc · Sites in United States
Ages 18+ · Men only
Astellas Pharma Global Development, Inc. · Sites in United States, China, Japan and 1 more country
Ages 18+
Duboce Biopharmaceuticals, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
307 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 124 · Phase 2 148 · Phase 3 28 · Phase 4 2
First in 1995; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 57 across 490 interventional studies indexed under Adenocarcinoma.
Median enrollment 48 across the 271 interventional studies, 148 across the 30 observational. Of the 207 that completed or were terminated, 94 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
136 of 307 have an industry lead sponsor. The 10 most frequent:
Opna Bio LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Opna Bio LLC has 1 study filed under Adenocarcinoma — fewer than ten, so there is no comparison to draw.
20 of the studies in Adenocarcinoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07182279The Methodist Hospital Research InstituteNeoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer | 2026-11-14 |
| NCT04644770Janssen Research & Development, LLCA Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | 2026-12-08 |
| NCT07332000Candel Therapeutics, Inc.A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | 2027-02 |
| NCT06636682Cellvax Therapeutics IncFK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | 2027-02-02 |
| NCT05873686Nuvectis Pharma, Inc.A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | 2027-03 |
Add all 20 to your calendar (.ics) → With an account.
Among the 307 studies in Adenocarcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active known second with the exception of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1b dose escalation
Drug: PLX2853 20 mg · Drug: Olaparib
Phase 1b dose escalation
Drug: Abiraterone acetate · Drug: Prednisone · Drug: PLX2853 40 mg
Phase 1b dose escalation
Drug: Abiraterone acetate · Drug: Prednisone · Drug: PLX2853 80 mg
Phase 2a dose expansion
Drug: Abiraterone acetate · Drug: Prednisone · Drug: PLX2853 80 mg
Phase 1b dose escalation
Drug: Olaparib · Drug: PLX2853 40 mg
PLX2853 tablets
Olaparib tablets
Abiraterone acetate tablets
Prednisone (or equivalent) tablets
PLX2853 tablets
PLX2853 tablets
Number of Participants With Dose-Limiting Toxicities
Dose limiting toxicity defined as clinically significant adverse events or laboratory abnormalities occurring during first cycle of study drug administration that are possibly related to study drug and that meet specific criteria defined in the protocol
Time frame: From time of first dose of PLX2853 and combination agent(s) through completion of Cycle 1 (21 days)
Phase 1b (Both Arms): Incidence of TEAEs That Are Related to Treatment
Treatment-emergent adverse events are those reported after study drug has been administered.
Time frame: From time of first dose of PLX2853 and combination agent(s) until 30 days from end of treatment (an average of 103 days)
Determination of Maximum Tolerated Dose
To be evaluated in both PLX2853 + AA + pred and PLX2853 + olap group; If DLTs observed in 2 or more subjects the dose will be considered intolerable and MTD will have been reached.
Time frame: From time of first dose of PLX2853 and combination agent(s) through completion of Cycle 1 (21 days)
| Milestone | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib |
|---|---|---|---|---|---|
| Started | 1 | 5 | 7 | 5 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 5 | 7 | 5 | 1 |
| Withdrew: Progressive disease | 0 | 2 | 2 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 1 | 0 |
| Withdrew: Psa increase | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Sponsor study termination | 1 | 0 | 0 | 0 | 0 |
Dose limiting toxicity defined as clinically significant adverse events or laboratory abnormalities occurring during first cycle of study drug administration that are possibly related to study drug and that meet specific criteria defined in the protocol
| participants | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib |
|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities | 0 | 0 | 0 | 0 | 0 |
Treatment-emergent adverse events are those reported after study drug has been administered.
| Participants | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib |
|---|---|---|---|---|---|
| Phase 1b (Both Arms): Incidence of TEAEs That Are Related to Treatment | 1 | 5 | 7 | 5 | 1 |
To be evaluated in both PLX2853 + AA + pred and PLX2853 + olap group; If DLTs observed in 2 or more subjects the dose will be considered intolerable and MTD will have been reached.
| mg | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib |
|---|---|---|---|---|---|
| Determination of Maximum Tolerated Dose | NA | NA | NA | NA | NA |
Collected over Through 30 days after last study drug, an average of 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b PLX2853 (20 mg) + Olaparib | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Phase 1b PLX2853 (40 mg) + Olaparib | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib |
|---|---|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/1 | 0/5 | 0/7 | 0/5 | 0/1 |
| Bone painMusculoskeletal and connective tissue disorders | 0/1 | 1/5 | 0/7 | 0/5 | 0/1 |
| Blood bilirubin increaseInfections and infestations | 0/1 | 0/5 | 0/7 | 1/5 | 0/1 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/1 | 0/5 | 0/7 | 1/5 | 0/1 |
| HyperglycemiaMetabolism and nutrition disorders | 0/1 | 0/5 | 1/7 | 0/5 | 0/1 |
| Urinary tract obstructionRenal and urinary disorders | 0/1 | 0/5 | 1/7 | 0/5 | 0/1 |
| SepsisInfections and infestations | 0/1 | 0/5 | 1/7 | 0/5 | 0/1 |
| Event | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib |
|---|---|---|---|---|---|
| anemiaBlood and lymphatic system disorders | 1/1 | 1/5 | 5/7 | 0/5 | 1/1 |
| pancytopeniaBlood and lymphatic system disorders | 1/1 | 0/5 | 0/7 | 5/5 | 0/1 |
| nauseaGastrointestinal disorders | 1/1 | 4/5 | 7/7 | 0/5 | 1/1 |
| urinary tract infectionRenal and urinary disorders | 1/1 | 0/5 | 0/7 | 0/5 | 0/1 |
| hypokalemiaMetabolism and nutrition disorders | 1/1 | 0/5 | 2/7 | 0/5 | 0/1 |
| hypophosphatemiaMetabolism and nutrition disorders | 1/1 | 0/5 | 1/7 | 0/5 | 0/1 |
| anorexiaMetabolism and nutrition disorders | 1/1 | 1/5 | 2/7 | 1/5 | 0/1 |
| pleural effusionRespiratory, thoracic and mediastinal disorders | 1/1 | 0/5 | 0/7 | 0/5 | 0/1 |
| diarrheaGastrointestinal disorders | 0/1 | 4/5 | 2/7 | 3/5 | 1/1 |
| fatigueGeneral disorders | 0/1 | 3/5 | 6/7 | 5/5 | 1/1 |
| Age, Continuous(years) | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib | Total |
|---|---|---|---|---|---|---|
| Mean | 69 (69 to 69) | 66.4 (60 to 78) | 68.9 (58 to 80) | 68.2 (63 to 76) | 73 (73 to 73) | 68.3 (58 to 80) |
| Sex: Female, Male(Participants) | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 1 | 5 | 7 | 5 | 1 | 19 |
| Race (NIH/OMB)(Participants) | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 0 | 2 |
| White | 1 | 3 | 2 | 3 | 0 | 9 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 2 | 1 | 1 | 5 |
| Region of Enrollment(participants) | Phase 1b PLX2853 (20 mg) + Olaparib | Phase 1b PLX2853 (40 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 2a PLX2853 (80 mg) + Abiraterone Acetate + Prednisone | Phase 1b PLX2853 (40 mg) + Olaparib | Total |
|---|---|---|---|---|---|---|
| United States | 1 | 5 | 7 | 5 | 1 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in May 2022, 20 months.
Results were first posted in Apr 2025, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zavabresib · Abiraterone Acetate · Prednisone
Opna Bio LLC